AliveCor

AliveCor is an AI-enabled remote patient monitoring company that develops mobile electrocardiogram (ECG) devices that track users’ heartbeats under its flagship brand KardiaMobile.

The FDA-approved solution is built on its proprietary technology, AI/ML-powered ECG sensors, and enables the detection of various cardiac conditions, such as atrial fibrillation, bradycardia, tachycardia, and sinus rhythm with supraventricular ectopy, in 30 seconds. 

The company’s cardiological care subscription services include 1) KardiaCare, which offers heart health insights and monitoring features, including unlimited ECGs and clinician review at USD 11.99 per month, and 2) KardiaPlus, which extends the KardiaCare membership with additional reviews, a KardiaMobile 6L device, and blood pressure cuff.  

Key customers and partnerships

As of January 2024, the company had served more than two million customers in over 40 countries.

The company has several key partners. These include the following: 

- Clario to enable ECG readings to be collected from trial participants’ homes ( August 2023 )

- Thomas Jefferson University Hospital to evaluate the benefits of QTc monitoring with KardiaMobile 6L for patients receiving methadone maintenance therapy for opioid use disorder ( July 2023 )

- PaceMate to create an integrated system that will facilitate the collection and evaluation of ECG data ( May 2023 )

- BIOTRONIK to combine BIOTRONIK's injectable cardiac monitor with AliveCor's ECG technology ( September 2022 )

- GE Healthcare to integrate ECG data from AliveCor's KardiaMobile 6L device directly into GE Healthcare’s MUSE Cardiac Management System for physicians to view and evaluate ( March 2022 )

- AstraZeneca to study disease management solutions using AliveCor’s Kardia-K technology ( February 2021 )

Funding and financials

In August 2022 , the company raised an undisclosed amount in a Series F funding round led by GE Healthcare. The funds were aimed at advancing its cardiological care subscription services.